The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
 
Rodrigo De Almeida Toledo
Research Funding - AstraZeneca; BeiGene; Novartis
 
Alma M Calahorro García
No Relationships to Disclose
 
Oriol Mirallas
Speakers' Bureau - ROVI
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Almirall; Sanofi
 
Ana Moreno
No Relationships to Disclose
 
Vladimir Galvao
No Relationships to Disclose
 
Guzmán Alonso
No Relationships to Disclose
 
Maria Vieito
Consulting or Advisory Role - BMS
Speakers' Bureau - Novocure
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche; Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Boehringer Ingelheim; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Merus; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tolremo (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Arjun Oberoi
No Relationships to Disclose
 
M. Julia Lostes-Bardaji
No Relationships to Disclose
 
Jose Jimenez
No Relationships to Disclose
 
Marta Sanz
No Relationships to Disclose
 
Cristina Viaplana
No Relationships to Disclose
 
Raquel Perez-Lopez
Employment - Vall d'Hebron University Hospital Institute of Oncology
Consulting or Advisory Role - Roche
Speakers' Bureau - Pfizer; Roche
Research Funding - AstraZeneca/MedImmune; Roche
Travel, Accommodations, Expenses - AstraZeneca/MedImmune (Inst)
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis; Targos GmbH
Consulting or Advisory Role - Bayer; MSD Oncology; Targos GmbH
Travel, Accommodations, Expenses - Novartis
 
Charles Abbott
Employment - Personalis
Stock and Other Ownership Interests - Personalis
 
Jason Pugh
Employment - Personalis
Stock and Other Ownership Interests - Personalis
 
Richard Chen
Employment - Personalis
Leadership - Personalis
Stock and Other Ownership Interests - Personalis
Patents, Royalties, Other Intellectual Property - Multiple Personalis technology patents
Travel, Accommodations, Expenses - Personalis
 
Sean Michael Boyle
Employment - Personalis
Stock and Other Ownership Interests - Personalis
Patents, Royalties, Other Intellectual Property - I have patents though my position and work at Personalis, Inc.
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Medscape; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)